Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles 2023: Technologies, Biomarker Cargo & Diagnostics

Extracellular Vesicles 2023: Technologies, Biomarker Cargo & Diagnostics Agenda

Co-Located Conference Agendas

Microphysiological Systems 2023: A Deep Dive into Technologies & Applications | Extracellular Vesicles 2023: Technologies, Biomarker Cargo & Diagnostics | Extracellular Vesicles 2023: Drug Delivery, Biologics & Therapeutics | Space Summit 2023: Chips in Space | 

Print Agenda

Wednesday, 26 July 2023


Conference Registration and Materials Pick-Up + Coffee

Session Title: Where Does the Field of EVs Stand, circa 2023?


Mei HeConference Chair

Welcome and Introduction by Conference Co-Chairperson
Mei He, Assistant Professor, University of Florida, United States of America


Michael GranerConference Chair

Welcome and Introduction by Conference Co-Chairperson
Michael Graner, Professor, Dept of Neurosurgery, University of Colorado Anschutz School of Medicine, United States of America


Lucia LanguinoKeynote Presentation

Extracellular Vesicle Integrins: Novel Opportunities for the Diagnosis and Therapy of Cancer
Lucia Languino, Professor of Cancer Biology, Thomas Jefferson University, United States of America

The benefits of cancer therapy mediated by small extracellular vesicles (sEVs) are: low immunogenicity, ability to infiltrate biological barriers and ‘targetability’.  Cancer cells cross-talk with the tumor microenvironment by releasing sEVs.  Our studies have revealed a role for integrins in sEVs in mediating cancer cell cross-talk with the tumor microenvironment.  After confirming the fidelity of the sEV preparations by electron microscopy, density gradient, and immunoblotting, we have determined that integrins are actively packaged into sEVs isolated from cancer cells.  sEVs mediate protein transfer of integrins to microvascular endothelial cells and increase the number of their junctions and tubules.  We have also demonstrated a cross-talk between prostate cancer cells and monocytes that affects macrophage functions and have suggested that inhibition of integrins might offer a novel immune–based therapeutic strategy in prostate cancer.  Overall, these studies show that sEVs from cancer cells may contribute to a horizontal propagation of integrin-associated phenotypes from cancer cells to the tumor microenvironment. We finally demonstrate that the sEVs circulating in plasma from prostate cancer patients contain higher levels of specific integrins, as compared to plasma sEVs from age-matched healthy subjects.  Our results suggest that specific integrins in cancer patient sEVs could be clinically useful as non-invasive biomarkers for cancer progression.


Dominique PV de KleijnKeynote Presentation

Plasma Extracellular Vesicles for Cardiovascular Disease
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands

Cardiovascular Disease (CVD) is with the cardiovascular events of Ischemic Heart Disease and Stroke, the number 1 and 2 cause of death in the world and expect to increase especially in Asia. We use plasma extracellular vesicle (EV) protein content of vesicles from plasma subfractions on plasma of stroke and periferal artery disease(PAD) patients, patients after carotid atherectomy (CEA) and patients suspected for chronic coronary syndrome (CCS). Using 25 ul of plasma, we developed an automated 96-well based protocol using sequential precipitation. Using samples of the AtheroExpress, the largest ongoing CEA biobank we try to early detect the risk of a second Major Adverse Cardiovascular Event (MACE: myocardial infarction, stroke or cardiovascular death) in PAD and CEA patients. Identification of such high risk patients is very important for possible (expensive) add-on pharmaceutical therapy or the decision to operate or not. Sequential procipitation for EV isolation is also used for the diagnosis of CCS.


Kristin KopperudKeynote Presentation

Low Earth Orbit Research Opportunities on the International Space Station
Kristin Kopperud, Program Director, Biomedicine, International Space Station National Laboratory, United States of America

Overview of the ISS National Laboratory, including its mission, role, and unique set of experimental conditions. I will also discuss some research opportunities, from past to upcoming, that are available to researchers desiring to conduct experiments in microgravity.


Mid-Morning Coffee Break and Networking in the Exhibit Hall


Characterization of Proteins and Extracellular RNAs in Vesicles and Viruses for Cancer and COVID-19 Detection
Eduardo Reategui, Distinguished Assistant Professor of Engineering , The Ohio State University, United States of America

Liquid biopsies consist of sampling and analysis of tumor-derived content from a blood draw, and they are rapidly gaining interest in the laboratory and clinic due to significant advantages over traditional tissue analysis (e.g., frequent sampling, less invasive). One “candidate” to develop liquid biopsy assays are extracellular vesicles (EVs). EVs are shed continuously from tumor cells as tiny lipid nanoparticles and have been identified in different biofluids. EVs can be used as a surrogate for tumor cells since they carry similar proteins, mRNAs, miRNAs, and DNAs. This presentation will describe an ultrasensitive detection method for in-situ simultaneous protein and RNA profiling of EV subpopulations at the single vesicle level by total internal reflection fluorescence (TIRF) microscopy. We recently leveraged our expertise into single virus particle characterization that outperforms standard antigen and molecular detection methods for SARS-CoV-2. Our different technologies' translational potential will be shown through proof of concept experiments performed with clinical samples from cancer and COVID-19 patients.


Effect of Plasma Exosome Isolation Methods on Multi-Omic Profiles in Cancer Patients and Healthy Controls
Liang Wang, Senior Member of Tumor Biology, Moffitt Cancer Center, United States of America

Circulating exosomes in the blood are promising tools for biomarker discovery in cancer. Due to their heterogeneity, different isolation methods may enrich distinct exosome cargos generating different omic profiles. In this presentation, I will share our recent study on the effects of plasma exosome isolation methods on multi-omic profiles in cancer patients and healthy controls. This study evaluated three exosome isolation methods including size exclusion chromatography, lectin binding, and TIM4 binding. For each exosome isolation method, molecular profiling analysis was performed included lipidome, metabolome, proteome and transcriptome. Our study shows clear difference in molecular profiles of the exosomes isolated using different methods. Our findings suggest that specific isolation methods select subpopulations which may significantly impact cancer biomarker discovery.


Networking Lunch - Network with Colleagues and Meet Exhibitors

Session Title: Technologies Driving EV Research Forward


Terry MorganKeynote Presentation

NanoFACs EV Sorting -- Strengths and Limitations
Terry Morgan, Professor, Oregon Health and Science University, United States of America


NanoFCM Technology Spotlight Presentation


Particle Metrix GmbH Technolology Spotlight Presentation


Next-Generation Nanoplasmonic Sensing Technologies for Multiplexed Single Extracellular Vesicle Analysis
Hyungsoon Im, Assistant Professor, Center for Systems Biology, Mass General Hospital (MGH)/Harvard Medical School, United States of America

Recent studies support single extracellular vesicle (EV) analysis technologies as the most promising option for early cancer detection and accurate quantification of tumor-derived EVs for longitudinal treatment monitoring. In this presentation, I will discuss our advanced nanoplasmonic EV analysis technologies for sensitive, robust, and multiplexed single EV analysis.


Mid-Afternoon Coffee Break and Networking in the Exhibit Hall


Andrew GodwinKeynote Presentation

Title to be Confirmed.
Andrew Godwin, Professor and Division Director, Genomic Diagnostics, Founding Director, Kansas Institute for Precision Medicine, Deputy Director, KU Cancer Center, University of Kansas Medical Center, United States of America


Fatah KashanchiKeynote Presentation

Cross Talk Between Viruses and EV Biogenesis
Fatah Kashanchi, Professor and Director of Research, Lab of Molecular Virology, George Mason University, United States of America

Most RNA and DNA viruses package and release their products (DNA, RNA, proteins) in EVs to avoid detection by the host immune system. In the current study we have addressed two main questions related to timing of the EV vs. virus release using HIV-1 as a model system, and have further found a new method of isolating viral populations that have never been described before. To date, it is not clear whether there is a timing difference between EV and virion release from infected cells. Here, we found that EVs precede the secretion of viral particles at 6 hrs post-transcriptional activation and release. This early EV release could shed light on how the contents of EVs are able to increase the susceptibility of viral infection, perhaps by priming the environment prior to viral egress or altering the progression of the cell cycle in recipient cells. We also have found that when separating EVs using differential ultracentrifugation, size exclusion chromatography or simple size filtration, there are at least three distinct sizes and functional viruses when using HIV-1 as a model system.  Validation of the data was performed utilizing blocking infectivity with broadly neutralizing antibodies or culturing the producer cell lines in the presence of anti-retroviral drugs to interfere with the production of infectious virions.  Collectively, our results show how viruses use EV pathways to release their cargo prior to virion release and the virions are very heterogenous in size, biochemical and biophysical characteristics.


Cytek BioSciences Technology Spotlight Presentation


The AlphaV-Beta3 Integrin/NgR2 Complex is Up-regulated in Prostate Cancer Cell-derived EVs and Patient-derived EVs and Represents a Promising Therapeutic Target
Anna Testa, Medical Resident, Thomas Jefferson University; Internal Medicine Fellow, University of Tur, United States of America

The AlphaV-Beta3 integrin, known to promote growth and metastasis of several types of cancer, is highly expressed in neuroendocrine prostate cancer (NEPrCa). PrCa cell-derived small extracellular vesicles (sEVs) expressing AlphaV-Beta3 contribute to NEPrCa differentiation in recipient cells. AlphaV-Beta3 integrin upregulates NgR2, a glycosylphosphatidylinositol-anchored receptor, in NEPrCa cells. By investigating the impact of AlphaV-Beta3 expression in sEVs on downstream protein expression via proteomic analysis, we demonstrate that AlphaV-Beta3+ sEVs also show an up-regulation in NgR2 expression; furthermore, a down-regulation of typical effectors involved in apoptosis and necrosis and an up-regulation of tumor cell survival factors emerge, as compared to control sEVs. We also show that EVs isolated from metastatic castrate-resistant prostate cancer (mCRPC) patients plasma are enriched in AlphaV-Beta3 and NgR2. sEVs used in these experiments were isolated by density gradient and characterized by nanoparticle tracking analysis and immunoblotting. Additionally, by testing the effect of AlphaV-Beta3 inhibition in NEPrCa-patient derived xenografts (PDXs) using LM609, a monoclonal antibody (mAb) specific for AlphaV-Beta3, we demonstrate a significant reduction of tumor volume and weight in NE-PDXs carrying mice upon treatment with LM609. Our findings suggest that AlphaV-Beta3 integrin and NgR2 are key components of NEPrCa progression and represent a promising therapeutic target both in vitro and in vivo.


Extracellular Vesicles-Enabled Liquid Biopsy for Cancer Diagnosis, Prognosis, and Treatment
Yong Zeng, Associate Professor, Department of Chemistry, University of Florida, United States of America

My research is primarily focused on the development of innovative liquid biopsy-based tests based on extracellular vesicles (EVs) and micro/nanobiosensing technologies for cancer diagnosis, prognosis, and treatment. Herein, we will discuss the nanoengineered systems and bioassays for efficient immunoisolation of circulating EVs and ultrasensitive profiling of EV biomarkers, including proteins and miRNAs.  Adaptation of our new technologies to clinical assessment of EV-based liquid biopsy for non-invasive detection, subtyping, and treatment monitoring of cancer will be demonstrated.


Close of Day 1 Conference Programming + Networking Reception with Beer and Wine


Close of Conference Day

Thursday, 27 July 2023

Please View Details of Programming under the EV Therapeutics Website

Add to Calendar ▼2023-07-26 00:00:002023-07-27 00:00:00Europe/LondonExtracellular Vesicles 2023: Technologies, Biomarker Cargo and DiagnosticsExtracellular Vesicles 2023: Technologies, Biomarker Cargo and Diagnostics in Orlando, FloridaOrlando,